获得性喉气管狭窄发生机制的研究进展

胡彬; 陈佳瑞; 李为; 汪景; 李晓艳

doi:10.13201/j.issn.2096-7993.2022.04.016

获得性喉气管狭窄发生机制的研究进展

- 1.
  上海市儿童医院上海交通大学附属儿童医院耳鼻喉科(上海, 200333)
- 2.
  河北省唐山市妇幼保健院
基金项目:
上海市“医苑新星”青年医学人才培养资助计划[沪卫计人事(2019)72号]

详细信息

通讯作者: 李晓艳，E-mail：chhshent@163.com

中图分类号: R767

收稿日期: 2021-04-19

刊出日期: 2022-04-03

An updated review of the mechanism of fibrosis in acquired laryngotrachealstenosis

More Information

Corresponding author: LI Xiaoyan, E-mail: chhshent@163.com

Received Date: 19 April 2021

Publish Date: 03 April 2022

摘要

- 喉气管狭窄 /
- 纤维化 /
- 成纤维细胞
Abstract: Acquired laryngotracheal stenosis is a laryngeal obstruction disease due to pathologic scar formation. Although acquired laryngotracheal stenosis is hypothesized to be related to fibrosis, its specific mechanisms have yet to be characterized. This article reviews the latest research progress on the mechanisms of laryngotracheal fibrosis, including metabolic changes, immune cell dysregulation, extracellular matrix changes and microbiota.
- laryngotracheal stenosis /
- fibrosis /
- fibroblast

HTML全文

参考文献(47)

[1]	王颖. 儿童喉气管狭窄的研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(21): 1684-1686. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201821019.htm
[2]	郭志华, 崔鹏程, 赵大庆, 等. 15例特发性声门下狭窄诊疗分析[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(2): 173-176. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202002018.htm
[3]	郭志华, 赵大庆, 邢园, 等. 复发性多软骨炎并发喉气管狭窄的诊断和治疗[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(6): 524-527. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202006012.htm
[4]	Hu B, Wang J, Chen J, et al. The heterogeneity of fibroblasts in laryngotracheal stenosis and skin hypertrophic scar in pediatric patients[J]. Int J Pediatr Otorhinolaryngol, 2021, 145: 110709. doi: 10.1016/j.ijporl.2021.110709
[5]	Ma G, Samad I, Motz K, et al. Metabolic variations in normal and fibrotic human laryngotracheal-derived fibroblasts: A Warburg-like effect[J]. Laryngoscope, 2017, 127(3): E107-E113. doi: 10.1002/lary.26254
[6]	Kang YP, Lee SB, Lee JM, et al. Metabolic Profiling Regarding Pathogenesis of Idiopathic Pulmonary Fibrosis[J]. J Proteome Res, 2016, 15(5): 1717-1724. doi: 10.1021/acs.jproteome.6b00156
[7]	Tsai HW, Motz KM, Ding D, et al. Inhibition of glutaminase to reverse fibrosis in iatrogenic laryngotracheal stenosis[J]. Laryngoscope, 2020, 130(12): E773-E781.
[8]	Murphy MK, Motz KM, Ding D, et al. Targeting metabolic abnormalities to reverse fibrosis in iatrogenic laryngotracheal stenosis[J]. Laryngoscope, 2018, 128(2): E59-E67. doi: 10.1002/lary.26893
[9]	Yin X, Choudhury M, Kang JH, et al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-beta[J]. Sci Signal, 2019, 12(612): eaax4067. doi: 10.1126/scisignal.aax4067
[10]	Andrianifahanana M, Hernandez DM, Yin X, et al. Profibrotic up-regulation of glucose transporter 1 by TGF-beta involves activation of MEK and mammalian target of rapamycin complex 2 pathways[J]. FASEB J, 2016, 30(11): 3733-3744. doi: 10.1096/fj.201600428R
[11]	Leone RD, Zhao L, Englert JM, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion[J]. Science, 2019, 366(6468): 1013-1021. doi: 10.1126/science.aav2588
[12]	Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells?[J]. Trends Biochem Sci, 2016, 41(3): 211-218. doi: 10.1016/j.tibs.2015.12.001
[13]	Li L, Liang Y, Kang L, et al. Transcriptional Regulation of the Warburg Effect in Cancer by SIX1[J]. Cancer Cell, 2018, 33(3): 368-385. e7. doi: 10.1016/j.ccell.2018.01.010
[14]	Micalizzi DS, Wang CA, Farabaugh SM, et al. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth[J]. Cancer Res, 2010, 70(24): 10371-10380. doi: 10.1158/0008-5472.CAN-10-1354
[15]	Xie N, Tan Z, Banerjee S, et al. Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis[J]. Am J Respir Crit Care Med, 2015, 192(12): 1462-1474. doi: 10.1164/rccm.201504-0780OC
[16]	Hu X, Xu Q, Wan H, et al. PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis[J]. Lab Invest, 2020, 100(6): 801-811. doi: 10.1038/s41374-020-0404-9
[17]	Romani P, Valcarcel-Jimenez L, Frezza C, et al. Crosstalk between mechanotransduction and metabolism[J]. Nat Rev Mol Cell Biol, 2021, 22(1): 22-38. doi: 10.1038/s41580-020-00306-w
[18]	Park JS, Burckhardt CJ, Lazcano R, et al. Mechanical regulation of glycolysis via cytoskeleton architecture[J]. Nature, 2020, 578(7796): 621-626. doi: 10.1038/s41586-020-1998-1
[19]	Zhao X, Kwan J, Yip K, et al. Targeting metabolic dysregulation for fibrosis therapy[J]. Nat Rev Drug Discov, 2020, 19(1): 57-75. doi: 10.1038/s41573-019-0040-5
[20]	Motz KM, Yin LX, Samad I, et al. Quantification of Inflammatory Markers in Laryngotracheal Stenosis[J]. Otolaryngol Head Neck Surg, 2017, 157(3): 466-472. doi: 10.1177/0194599817706930
[21]	Hillel AT, Ding D, Samad I, et al. T-Helper 2 Lymphocyte Immunophenotype Is Associated With Iatrogenic Laryngotracheal Stenosis[J]. Laryngoscope, 2019, 129(1): 177-186. doi: 10.1002/lary.27321
[22]	Ghosh A, Malaisrie N, Leahy KP, et al. Cellular adaptive inflammation mediates airway granulation in a murine model of subglottic stenosis[J]. Otolaryngol Head Neck Surg, 2011, 144(6): 927-933. doi: 10.1177/0194599810397750
[23]	Motz K, Samad I, Yin LX, et al. Interferon-γ Treatment of Human Laryngotracheal Stenosis-Derived Fibroblasts[J]. JAMA Otolaryngol Head Neck Surg, 2017, 143(11): 1134-1140. doi: 10.1001/jamaoto.2017.0977
[24]	Gieseck RL, 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis[J]. Nat Rev Immunol, 2018, 18(1): 62-76. doi: 10.1038/nri.2017.90
[25]	Dong Y, Yang M, Zhang J, et al. Depletion of CD8+ T Cells Exacerbates CD4+ T Cell-Induced Monocyte-to-Fibroblast Transition in Renal Fibrosis[J]. J Immunol, 2016, 196(4): 1874-1881. doi: 10.4049/jimmunol.1501232
[26]	Motz K, Lina I, Murphy MK, et al. M2 Macrophages Promote Collagen Expression and Synthesis in Laryngotracheal Stenosis Fibroblasts[J]. Laryngoscope, 2021, 131(2): E346-E353.
[27]	Satoh T, Nakagawa K, Sugihara F, et al. Identification of an atypical monocyte and committed progenitor involved in fibrosis[J]. Nature, 2017, 541(7635): 96-101. doi: 10.1038/nature20611
[28]	Aghajanian H, Kimura T, Rurik JG, et al. Targeting cardiac fibrosis with engineered T cells[J]. Nature, 2019, 573(7774): 430-433. doi: 10.1038/s41586-019-1546-z
[29]	Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis[J]. J Clin Invest, 2018, 128(1): 45-53. doi: 10.1172/JCI93557
[30]	Liu G, Cooley MA, Nair PM, et al. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c[J]. J Pathol, 2017, 243(4): 510-523. doi: 10.1002/path.4979
[31]	O'dwyer DN, Moore BB. The role of periostin in lung fibrosis and airway remodeling[J]. Cell Mol Life Sci, 2017, 74(23): 4305-4314. doi: 10.1007/s00018-017-2649-z
[32]	Philp CJ, Siebeke I, Clements D, et al. Extracellular Matrix Cross-Linking Enhances Fibroblast Growth and Protects against Matrix Proteolysis in Lung Fibrosis[J]. Am J Respir Cell Mol Biol, 2018, 58(5): 594-603. doi: 10.1165/rcmb.2016-0379OC
[33]	Roderfeld M, Rath T, Pasupuleti S, et al. Bone marrow transplantation improves hepatic fibrosis in Abcb4-/-mice via Th1 response and matrix metalloproteinase activity[J]. Gut, 2012, 61(6): 907-916. doi: 10.1136/gutjnl-2011-300608
[34]	Mazhar K, Gunawardana M, Webster P, et al. Bacterial biofilms and increased bacterial counts are associated with airway stenosis[J]. Otolaryngol Head Neck Surg, 2014, 150(5): 834-840. doi: 10.1177/0194599814522765
[35]	Harkness LM, Weckmann M, Kopp M, et al. Tumstatin regulates the angiogenic and inflammatory potential of airway smooth muscle extracellular matrix[J]. J Cell Mol Med, 2017, 21(12): 3288-3297. doi: 10.1111/jcmm.13232
[36]	Fuja TJ, Probst-Fuja MN, Titze IR. Changes in expression of extracellular matrix genes, fibrogenic factors, and actin cytoskeletal organization in retinol treated and untreated vocal fold stellate cells[J]. Matrix Biol, 2006, 25(1): 59-67. doi: 10.1016/j.matbio.2005.08.005
[37]	Olmos-Zuniga JR, Baltazares-Lipp M, Hernandez-Jimenez C, et al. Treatment with Hyaluronic Acid and Collagen-Polyvinylpyrrolidone Improves Extracellular Matrix Assembly for Scarring after Tracheal Resection[J]. Biomed Res Int, 2020, 2020: 3964518.
[38]	Upagupta C, Shimbori C, Alsilmi R, Kolb M. Matrix abnormalities in pulmonary fibrosis[J]. Eur Respir Rev, 2018, 27(148): 180033. doi: 10.1183/16000617.0033-2018
[39]	Gross JH, Giraldez-Rodriguez LA, Klein AM. Bacterial Laryngotracheitis and Associated Upper Airway Obstruction: A Case Series[J]. Ann Otol Rhinol Laryngol, 2015, 124(12): 1002-1005. doi: 10.1177/0003489415592161
[40]	Hillel AT, Tang SS, Carlos C, et al. Laryngotracheal Microbiota in Adult Laryngotracheal Stenosis[J]. mSphere, 2019, 4(3): e00211-00219.
[41]	Leite C, de Freitas F, de Cássia Firmida M, et al. Analysis of airway microbiota in adults from a Brazilian cystic fibrosis center[J]. Braz J Microbiol, 2020, 51(4): 1747-1755. doi: 10.1007/s42770-020-00381-3
[42]	O'Dwyer DN, Ashley SL, Gurczynski SJ, et al. Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis[J]. Am J Respir Crit Care Med, 2019, 199(9): 1127-1138. doi: 10.1164/rccm.201809-1650OC
[43]	Dickson RP, Harari S, Kolb M. Making the case for causality: what role do lung microbiota play in idiopathic pulmonary fibrosis?[J]. Eur Respir J, 2020, 55(4): 2000318. doi: 10.1183/13993003.00318-2020
[44]	Invernizzi R, Barnett J, Rawal B, et al. Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent[J]. Eur Respir J, 2020, 55(4): 1901519. doi: 10.1183/13993003.01519-2019
[45]	Bora SA, Kennett MJ, Smith PB, et al. The Gut Microbiota Regulates Endocrine Vitamin D Metabolism through Fibroblast Growth Factor 23[J]. Front Immunol, 2018, 9: 408. doi: 10.3389/fimmu.2018.00408
[46]	Lang S, Farowski F, Martin A, et al. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools[J]. Sci Rep, 2020, 10(1): 9385. doi: 10.1038/s41598-020-66241-0
[47]	Loomba R, Seguritan V, Li W, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease[J]. Cell Metab, 2019, 30(3): 607. doi: 10.1016/j.cmet.2019.08.002